Print Page      Close Window

Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 2/3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA.
NASDAQ GS TOCA (Common Stock)
$9.990.00
Stock chart for: TOCA.O.  Currently trading at $9.99 with a 52 week high of $17.95 and a 52 week low of $9.65.
10/19/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

10/17/17

Read More

Tocagen Reports Second Quarter 2017 Financial and Business Results

08/09/17

Read More

Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9

08/02/17

Read More

Recent Presentation

View All  
DateTitle
06/22/17
Download Documentation Corporate Presentation – June 20, 2017

Upcoming Events

View All  
There are currently no events scheduled.